Doctronic secures major funding for AI-powered telemedicine
Doctronic 為人工智慧遠距醫療項目獲得大額融資
In a move that could redefine modern medicine, New York-based startup Doctronic has secured $40 million in Series B funding.
紐約的新創公司Doctronic在近期籌集了4000萬美元的B輪融資，此舉可能重新定義現代醫學。
Founded in 2023, the company aims to tackle the U.S. healthcare access crisis by using an AI-native platform.
該公司成立於2023年，旨在透過「人工智慧原生」(AI-native)平台解決美國醫療保健的可及性危機。
Unlike basic symptom checkers, Doctronic utilizes a unique multi-agent system where specialized AI agents simulate clinical grand rounds to formulate diagnoses, which are then validated by human doctors.
與基礎的症狀檢查工具不同，Doctronic利用一套獨特的多代理人系統，模擬臨床大型巡迴查房來制定診斷，隨後由人類醫生進行驗證。
Operating in all 50 U.S. states, the company has seen massive adoption, with over 300,000 unique visitors weekly.
該公司在美國全境50州運作，已獲得極大的採納率，每週擁有超過30萬名獨立訪客。
Recently, Doctronic hit a regulatory milestone by launching a pilot program in Utah, allowing AI to handle routine prescription refills.
近日，Doctronic在猶他州啟動了一項試點計畫，允許人工智慧處理常規處方箋續配，達成了監管里程碑。
Despite facing some scrutiny regarding safety vulnerabilities—which the company maintains do not impact their regulated pilot—Doctronic remains at the forefront of the shift toward AI-autonomous care.
儘管面臨關於安全漏洞的一些審視——公司堅持這些漏洞並不影響其受監管的試點計畫——Doctronic仍站在邁向人工智慧自主照護轉型的前沿。
By bridging the gap between "Dr.
透過填補「Google醫師」與傳統初級照護之間的缺口，Doctronic證明了人工智慧可以為醫療結果承擔法律責任，為更有效率、更可及的未來鋪平道路。
Google" and traditional primary care, Doctronic is proving that AI can take legal responsibility for health outcomes, paving the way for a more efficient, accessible future.
